Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, BridgeBio Pharma, Inc. reported revenue of $502M, up 126.3% year over year. Operating margin was -104.2% and net margin -146.0%, on a free-cash-flow margin of -89.0% with capital expenditure at 0.2% of revenue. Every figure is computed directly from BBIO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $502M | -104.2% | -146.0% |
| FY2024 | $222M | -267.2% | -244.9% |
| FY2023 | $9M | -6528.8% | -7021.9% |
| FY2022 | $78M | -659.6% | -624.2% |
| FY2021 | $70M | -827.1% | -841.2% |
How does BBIO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.